Bioventus Inc - Class A

Bioventus posted a solid second quarter, beating Wall Street expectations on both the top and bottom lines as underlying business momentum cut through the noise of its recent divestiture. The Durham-based orthobiologics company reported non-GAAP EPS of $0.21, ahead of the $0.20 consensus estimate by 6.76%, while revenue of $147.66 million edged past the $145.86 million consensus by 1.23%, even as reported sales slipped 2.4% year-over-year following the sale of its Advanced Rehabilitation Business. The headline revenue decline masked a 6.2% organic growth rate, with double-digit organic gains in both Surgical Solutions and Restorative Therapies fueling the outperformance. The company also swung to GAAP net income of $7.46 million from a net loss of $25.68 million a year ago, when a non-cash impairment charge and shareholder litigation costs weighed heavily on results. Looking ahead, management reiterated full-year 2025 guidance calling for net sales of $560 million to $570 million and non-GAAP EPS of $0.64 to $0.68, representing growth of up to 38.8%.